Latest Breaking News On - ஆண்ட்ரே கலில் - Page 1 : comparemela.com

But drug did not reduce disease progression in COV-BARRIER trial Treatment of hospitalized Covid-19 patients with the selective Janus kinase (JAK) inhibitor baricitinib, along with standard of care including dexamethasone, was associated with reduced mortality but not reduction in disease progression in the international, multicenter, phase III COV-BARRIER randomized trial. Baricitinib plus standard of care

United statesCity ofUnited kingdomAndre kalilPsalynn boylesVincent marconiJustin stebbingImperial college londonUniversity of nebraska medical centerEmory university school of medicineLancet respiratoryEmory university schoolNorth americaNebraska medical centerContributing writerஒன்றுபட்டது மாநிலங்களில்